Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
Open Access
- 9 January 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e807-e815
Abstract
Background: As the test verification core for the Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP), we conducted independent bench- and field-based performance testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A&B lateral flow assays (LFAs) prior to formal clinical studies for Food and Drug Administration (FDA) submission. Methods: During bench testing, the limit of detection (LOD) was approximated using serially diluted panels of laboratory-propagated virus. In field studies, LFA results were interpreted by study participants, and sensitivity and specificity were determined using reverse transcription polymerase chain reaction (RT-PCR) (Xpert CoV-2/Flu/RSV plus) from a concurrent nasal swab as the reference standard. Results: Between February 2023 and February 2025, we tested 30 iterations of 14 LFAs. LODs were 53 277–1 393 314 genome equivalents (GE)/mL for SARS-CoV-2, 85 027–1 731 676 for influenza A, and 11 688–2 960 941 for influenza B. Field studies enrolled 27 to 126 participants per LFA with most enrolling at least 50 participants. When minimum 5 positive cases were enrolled, sensitivity ranged from 0.57–1.00 for SARS-CoV-2 and 0.64–0.85 for influenza A. Influenza B case enrollment was low. Specificity ranged from 0.91–1.00 across all targets. Eleven of 14 devices underwent at least two iterations of testing. Following ITAP assessment, 7 devices received FDA emergency use authorization, and 3 ultimately received de novo marketing approval or 510 (k) clearance. Conclusions: The ITAP enabled rapid feedback to federal agencies and manufacturers on the analytical and clinical performance of over-the-counter LFAs for SARS-CoV-2 and influenza, ultimately contributing to success in regulatory authorization or clearance.Keywords
Funding Information
- National Institutes of Health (U54EB027690 02S1)
- National Institutes of Health (U54EB027690 03S1)
- National Institutes of Health (U54EB027690 03S2)
- National Institutes of Health (75N92022D00015)
- National Institutes of Health (75N92023F00001)
This publication has 20 references indexed in Scilit:
- The SARS-CoV-2 test scale-up in the USA: an analysis of the number of tests produced and used over time and their modelled impact on the COVID-19 pandemicThe Lancet Public Health, 2025
- Protocol for the creation and characterization of SARS-CoV-2 variant testing panels using remnant clinical samples for diagnostic assay testingSTAR Protocols, 2024
- Laboratory Verification and Clinical Validation of COVID-19 Diagnostic Assays2024
- Unreported SARS-CoV-2 Home Testing and Test PositivityJAMA Network Open, 2023
- Don’t forget about human factors: Lessons learned from COVID-19 point-of-care testingCell Reports Methods, 2022
- Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 InfectionJAMA Internal Medicine, 2022
- How COVID-19 is changing the cold and flu seasonNature, 2020
- Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States — The NIH RADx InitiativeNew England Journal of Medicine, 2020
- Evaluation of high‐throughput digital lateral flow immunoassays for the detection of influenza A/B viruses from clinical swab samplesJournal of Medical Virology, 2019
- Lateral flow assaysEssays in Biochemistry, 2016